嵌合抗原受体
医学
人口
肿瘤科
淋巴瘤
自体干细胞移植
移植
内科学
耐火材料(行星科学)
免疫学
免疫疗法
癌症
生物
天体生物学
环境卫生
作者
Samuel Vic,Jean Lemoine,Philippe Armand,François Lemonnier,Roch Houot
标识
DOI:10.1016/j.ejca.2022.08.019
摘要
Autologous stem cell transplantation (ASCT) and chimeric antigen receptor (CAR) T-cells are two therapeutic options for relapsed/refractory diffuse large B-cell lymphoma. Both are intensive and potentially curative therapies but differ in their efficacy and toxicity. ASCT may be offered to 'fit' patients (i.e. usually young with limited comorbidities) with chemosensitive disease. On the other hand, real world studies have shown that CAR T-cells may be safely administered to less fit and older patients. Thus, there is a potentially significant population of patients who may be offered CAR T-cell therapy despite not being eligible for ASCT. As the relative role of ASCT and CAR T-cells evolves, recognising and defining this population may be increasingly relevant. Here, we review criteria which may help identify this 'ASCT-ineligible but CAR T-cells eligible' population of patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI